займ на картузайм на карту срочно без отказа

Neurodyn Inc. to showcase its newest innovations at international convention

Posted on Jun 2, 2016 in News

(Charlottetown, PE, June 2, 2016) Neurodyn Life Sciences will take part in the BIO International Convention from June 4 to 9 in San Francisco, California. It’s the largest annual meeting and exhibition for the biotechnology industry in the world. Neurodyn will participate alongside a delegation of bioscience-based companies from Atlantic Canada, led by the Atlantic Canada Bio-Industries Alliance (ACBA). The company intends to update potential co-development and licensing partners on its clinical-stage Alzheimer’s disease drug candidate, Memogain, and carry-out a series of meetings with potential collaborators on its neuropathic pain program. “We are eager to once again participate in BIO 2016,” says Ken Cawkell, CEO of Neurodyn. “This event enables our company to showcase our unique technologies and gain exposure for research and commercialization opportunities that are critical to our development programs.” Neurodyn’s business development and scientific teams will participate in one-on-one partnering meetings, an Atlantic Canadian Bio-Partnering breakfast, and other networking mixers throughout the week. About Neurodyn:  Neurodyn (www.neurodyn.ca) is a Canadian biotechnology company focused on identifying, validating and developing natural compounds into both prescription drugs and natural products for the early treatment of neurological diseases. Through its offices in Charlottetown, Halifax, and Germany, Neurodyn manages prescription drug and natural health product commercialization as well as subsidiaries in fine chemicals & medicinal chemistry and animal modeling of neurological disease. Contacts: Mr. Kenneth Cawkell, Chief Executive Officer kcawkell@neurodyn.ca  | 1.604.619.0990 Dr. Denis Kay, Chief Scientific Officer dgkay@neurodyn.ca  | 1.902.314.0776 Mr. Robert Cervelli, Executive Director cerveli@neurodyn.ca  |...

Read More

Neurodyn Announces Close of $1 Million Private Placement

Posted on Mar 31, 2015 in News

(Charlottetown, PE, March 31, 2015) Neurodyn Life Sciences Inc. (‘Neurodyn’ or the ‘Company’), today announced it has completed a $1 million funding round from existing shareholders and a range of investors in both Canada and the US including certain US family-managed venture funds. The Company will use the funds to support development and commercial initiatives across its product line of bioactive pharmaceuticals and natural health products including the Company’s revolutionary new Alzheimer’s drug, Memogain®; and a new cognitive enhancing emulsion, Cerbella™. “Investors are excited about the near-term potential of our product pipeline. Like us, they recognize the devastating socio-economic impact of an aging population that is becoming increasingly more susceptible to neurological disease,” says Ken Cawkell, CEO of Neurodyn. Memogain® is Neurodyn’s patent-protected improvement of the natural cognitive enhancer galantamine, which is currently used for the treatment of mild to moderate Alzheimer’s disease. Our Phase 1A clinical trial results demonstrated that Memogain’s design promotes higher preference for the brain, and thus fewer adverse side effects while at the same time providing higher cognitive enhancement, compared to presently marketed Alzheimer’s drugs. “Recent regulatory meetings in the EU suggest that Memogain® could be the next Alzheimer’s drug approved in Europe,” says Cawkell. “EU regulators have commented that Memogain® could qualify for their Innovative Medicines Initiative, designed to expedite new drugs to market.” Cerbella™ is Neurodyn’s highly bioavailable formulation of ginsensosides and green tea catechins, which are complexed and delivered in a flavored Omega-3 emulsion. Both its proprietary formulation and state-of-the-art packaging will revolutionize the way consumers think about brain health. The Company anticipates Cerbella™ will launch in the US and Canadian markets later this year. About Neurodyn:  Neurodyn (www.neurodyn.ca) is a Canadian biotechnology company focused on identifying, validating and developing natural compounds into both prescription drugs and natural products for the early treatment of neurological diseases. Through its offices in Charlottetown, Halifax, and Germany, Neurodyn manages prescription drug and natural health product commercialization as well as subsidiaries in fine chemicals & medicinal chemistry and animal modeling of neurological disease. Contacts: Mr. Kenneth Cawkell, Chief Executive Officer kcawkell@neurodyn.ca  | 1.604.619.0990   Dr. Denis Kay, Chief Scientific Officer dgkay@neurodyn.ca  | 1.902.314.0776   Mr. Robert Cervelli, Executive Director cerveli@neurodyn.ca  | 1.902.222.4391   Dr. Alfred Maelicke, Managing Director Europe alfred.maelicke@neurodyn.eu   The statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from Neurodyn’s expectations and...

Read More

Neurodyn collaborates with Van Kampen’s Greenhouses to bring hydroponic ginseng production to Prince Edward Island

Posted on Feb 26, 2015 in News

(Charlottetown, PE, February 26, 2015) Neurodyn Life Sciences announced today it has collaborated with one of the Island’s largest and most iconic greenhouse operations – Van Kampen’s Greenhouses – on a pilot study to grow a test plot of ginseng using a hydroponic growing method. It will be evaluated to determine the potential to create a stable, reliable, and clean local supply of one of the company’s key bioactives – Panax ginseng. Neurodyn has a need for a steady, clean (fungicide/pesticide free) supply of ginseng at an affordable cost for its ginsenoside-based products, NeuroPro® and Cerbella™. NeuroPro® is a brain health supplement launched in the Fall 2013. Given its popularity and success, a second generation ginseng-based product, Cerbella™, is being developed and slated to be on the market in Spring 2015. Neurodyn is committed to producing products that meet the highest industry standards for purity and potency and faces increasing challenges in finding a clean and consistent source of ginseng extract. “Despite what is happening in the international ginseng markets, we will not compromise the high quality of our products and are looking for innovative ways to grow our own supply of ginseng. Why look any further for experienced growers than our own backyard,” says Ken Cawkell, President & CEO of Neurodyn. Van Kampen’s Greenhouses will grow the plants hydroponically. Unlike traditional ginseng production, this method greatly shortens the growing time, eliminates the need for fungicides, and may yield a more concentrated ginsenoside profile. The project is under the supervision of Charles Van Kampen, who has operated a commercial-scale hydroponic tomato crop for over 30 years and whose expertise is critical to the success of this study. “Ginseng is a challenging crop that takes patience. The seeds are expected to take 20 weeks to germinate followed by a 14 week cold period and finally a 1 year growth term,” says Van Kampen. “We are excited and optimistic that PEI may soon be home to a new hydroponic ginseng operation.” The project is expected to take a year and a half. Should the findings of this study meet expectations, Neurodyn is prepared to explore a full production operation in Prince Edward Island, making this local supplier the primary source of ginsenosides for NeuroPro® and Cerbella™. The project is cost shared by the Growing Forward 2 (GF2) program administered by the Prince Edward Island Department of Agriculture and Forestry in conjunction with Agriculture and Agri-food Canada and is a comprehensive federal-provincial-territorial framework aimed at encouraging innovation, competitiveness and market development in Canada’s agri-food and agri-products sector. About: Neurodyn Life Sciences (www.neurodyn.ca) is a Canadian biotechnology company focused on identifying, validating and developing natural compounds into both prescription drugs and natural products...

Read More

NeuroQuest Inc. announces synthetic chemistry services

Posted on Nov 13, 2014 in News

(November 12, 2014 | Halifax)  Neurodyn Life Sciences Inc. announced today that the company’s wholly owned contract research subsidiary NeuroQuest Inc. is offering synthetic chemistry, medicinal chemistry and fine chemical production services to the research and biopharmaceutical industry. The medicinal chemistry services, which can be viewed here, include: –        Synthetic route optimization and synthesis (mg to gm quantities) –        Medicinal structure-based design or fragment-based design and HTS Hit analysis –        Synthesis of focussed library, SAR and ADMET optimization –        IP protection around NCE’s –        Electrophysiology (DRG patch clamp, state dependency, Nav selectivity) –        Other neurological assays These services include NMR and GC-LC-Mass Spec analysis including compound identification whether obtained from natural sources or designed and produced by synthesis. NeuroQuest’s fine chemicals services include the ability to solve complex chemical problems and the company can custom manufacture novel building blocks or scaffolds, intermediates or other fine chemicals.  NeuroQuest has expertise in phytosterols and other related bioactives. “We are pleased to be able to offer these services to the Atlantic regional biotech industry and other institutional researchers, as well as globally,” said Robert Cervelli, CEO of NeuroQuest. NeuroQuest works closely with its sister company CNS CRO (www.cnscro.com), which offers a wide range of animal models as a contract service.  The combined expertise makes both companies leaders in pre-clinical contract research for neurological conditions. Both NeuroQuest and CNS CRO are subsidiaries of Neurodyn Inc. (www.neurodyn.ca), a Canadian biotechnology company developing both prescription drugs and natural products for the early stage treatment of neurological diseases.   For more information, contact: Dr. Alexander McLellan                                    902-402-1775 (mobile)                   mclellan@neuroquest.ca Mr. Robert Cervelli                           902-222-4391 (mobile)                   cervelli@neuroquest.ca Dr. Denis Kay                                          902-314 0776 (mobile)                   dgkay@neurodyn.ca NeuroQuest Inc., Suite 365, 1411 Oxford Street, Halifax, NS B3H 3Z1...

Read More

Positive Phase 1a outcome for Memogain® means potential new treatment for Alzheimer’s disease

Posted on Sep 11, 2014 in News

(September 9, 2014 – Charlottetown, Prince Edward Island) Neurodyn Life Sciences Inc. announced completion of its first-in-human clinical study, demonstrating Memogain’s potential benefits over existing Alzheimer’s drugs;   increased safety in the absence of significant  side effects, more potent cognitive enhancement. The Phase IA clinical trial addressed safety, tolerability, and pharmacokinetics of intranasally delivered Memogain® in healthy young and elderly subjects, compared to the daily recommended doses of the current Alzheimer’s drugs: galantamine (16 mg) and donepezil (10 mg). Study participants were additionally tested for improved cognition. The administration of Memogain® was found to be safe and well tolerated at all dose levels. No clinical abnormalities were seen in hematology, blood chemistry, urine analysis, ECG or vital signs. Adverse events were either mild or moderate. The most prevalent being nausea, reported by a few subjects administered the standard galantamine dose of 16 mg, but only observed at the highest Memogain® dose (44mg). The excellent safety and tolerability of Memogain®, will dispense with the month-long gradual dosage increase that presently is common practice for other Alzheimer’s drugs, permitting the immediate administration of an efficacious dose. “This outstanding safety and tolerability profile is achieved even though Memogain®, a prodrug of galantamine, has a 10 times higher concentration in the brain, as compared to orally administered galantamine” says Dr. Maelicke, Memogain’s developer. “Additionally, Memogain® has a delayed release profile which could facilitate single daily dosing.” In cognitive testing, Memogain® was able to improve vigilance and short-term memory capacity: eye-hand coordination and vigilance was measured in the adaptive tracking test, and word learning and recall in the visual verbal learning test (VVLT). Both young and elderly subjects performed better than untreated volunteers in these tests. Galantamine, failed to show improvement in either the adaptive tracking test, or the VVLT, where donepezil also failed to demonstrate improvement. Earlier preclinical studies have demonstrated Memogain’s potential to provide neuroprotection and delay disease progression. Should future clinical studies also substantiate these findings, Memogain® may become the urgently needed turning point in the treatment of Alzheimer’s and other neurodegenerative diseases such as Parkinson’s disease. About Memogain (GLN-1062):  Memogain is a patent-protected synthetic derivative of the natural cognitive enhancer galantamine, which is currently used for the treatment of mild to moderate Alzheimer’s disease. Memogain is, an inactive form of galantamine that has more than a 10 fold higher preference for the brain than native galantamine. Once in the brain, the Memogain delivery vehicle is in effect ‘stripped off’ to reveal the active drug galantamine.  In this way Memogain is able to produce much higher brain levels of galantamine than can be achieved by the current oral administration. The Phase 1A results have demonstrated that Memogain’s design promotes higher preference...

Read More

Neurodyn Inc. creates Memogain® Advisory Board

Posted on Feb 24, 2014 in News

(February 21, 2014) Neurodyn Inc. commenced a Phase 1A clinical trial of its Alzheimer’s drug Memogain® in December 2013. In order to further support the Memogain Development Program, the company has assembled a advisory board of respected industry leaders to assist and guide the company as it plans the regulatory pathway for this promising Alzheimer’s prescription drug candidate. As a pro-drug of an already approved Alzheimer’s disease drug, with a much improved safety and efficacy profile, Memogain® may qualify for a more rapid and less costly path to market authorization by the US FDA.   Drs. Jim Olds, Chris Fibiger, Barry Greenberg and Mr. Jack Kay were named to the Memogain® Advisory Board. Each of them has made significant contributions in neuroscientific research, drug discovery, and pharmaceutical development worldwide.   Dr. Jim Olds earned his PhD in neurosciences and is currently the Director of the Krasnow Institute for Advanced Study, Professor of Neuroscience as well as Chair of the Department of Molecular Neuroscience at George Mason University, Virginia.  Additionally, he has an academic faculty appointment at the Department of Anatomy and Cell Biology at the Uniformed Services University of the Health Sciences in Maryland. In August 2004, he was named editor-in-chief of the journal Biological Bulletin.   Dr. Chris Fibiger was once among the top 100 most cited scientists in neuroscience. He was formerly Vice President and Global Head of Neuroscience at Amgen, a multinational biopharmaceutical company, where he led worldwide neuroscience discovery efforts ranging from early exploratory research through clinical candidate selection. He is now the Chief Scientific Officer for Medgenesis Therapeutics Inc.   Dr. Barry Greenberg has been involved in Alzheimer’s disease research and drug discovery since 1985. He is now Director of Neuroscience Drug Discovery & Development at the University Health Network and co-directing the Toronto Dementia Research Alliance as Director of Strategy, a consortium involving academic research and the five memory clinics at hospitals affiliated with the University of Toronto to create a citywide dementia research center.   Mr. Jack Kay has worked in the pharmaceutical industry for over 45 years, and, since 1995 has been President and Chief Operating Officer of Apotex Inc., the largest Canadian-owned group of pharmaceutical companies.   “We are thankful to be able to benefit from the guidance and insights of these recognized experts,” says Kenneth Cawkell, Neurodyn’s CEO. “Together, they will bring many years of experience and perspective to our task of optimizing our development strategy for Memogain®and ensure its successful commercialization.”     For more information, please contact: Neurodyn Life Science Inc.               Dr. Denis G. Kay, CSO                        +1 902 314...

Read More